TeamDrive
RUS
Vladimir Gurdus

Vladimir Gurdus

Founding Partner, COO

Телефоны:

+7 495 545-39-12

Send message

Vladimir is the co-founder and member of the Board of Directors of Doctor Ryadom (a private network of medical clinics). He is also the CEO and founder partner of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is Russian innovation pharmaceutical company NovaMedica LLC.

Vladimir is one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the U.S. firm Domain Associates LLC. RusnanoMedInvest was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Before assuming a key role as one of the project’s leaders and founding Team Drive, from 2007 to 2009 Vladimir was President at Medsi Group (part of AFK Sistema) and played a key role in transforming it into the leading privately-held medical service provider. Previously he had played an active role in starting up the ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding.  From 1991 to 2007 he was First Deputy CEO of ROSNO, and also the COO and CEO of ROSNO Group subsidiaries, such as ROSNO-MS. In 2006, after the acquisition of ROSNO by Allianz, Vladimir was appointed CEO of Allianz ROSNO-Life.

He is also an investor and the founder of a number of successful start-ups in the medical, insurance and IT sectors.

Vladimir is a member of the Government Expert Council of the Russian Federation. This organisation was established to involve the business community in the preparation and implementation of the decisions of the Russian Government, and also to ensure public oversight over the work of the federal authorities. Members of the Council attend the meetings of the Russian government, government and interdepartmental commissions and committees, and perform expert reviews of the draft decisions of the Russian government and federal executive agencies and the results of implementation. As a member of the Expert Council Vladimir proactively tackles issues of developing the Russian healthcare and pharmaceutical sectors. He also co-chairs a joint working group of the Expert Council and the Ministry of Health, whose chief remit is to draft the development framework of a healthcare system and the provision of the medicines required by the Russian population drug.

Vladimir is a member of the Public Council under the Ministry of Health of the Russian Federation – a permanent consultative public health oversight body.

Vladimir graduated cum laude from I.M. Sechenov Moscow Medical Academy. He has a second degree in finance and economics at RosNOU. Vladimir is a Doctor of Medical Sciences and Professor.

Media Center

  • 16 February 2018

    Pfizer taps BC for real-world cardiovascular research drive

    Pfizer has teamed up with BC Platforms to generate real-world evidence on cardiovascular diseases. The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.

  • 16 February 2018

    Pharma and AI: Help doctors with AI assistants but don’t try to replace them

    Dr. Robot gets a thumbs down from patients, according to new research from Syneos Health. Despite tech and investor enthusiasm, along with media headlines highlighting artificial intelligence in healthcare, patients are adamant that artificial intelligence should not replace doctors.

  • 15 February 2018

    Pharma Looks to Change the Healthcare Cost Conversation

    Amidst the continuing clamor for government action to curb prescription drug prices, a more collaborative effort aims to broaden the debate to consider the full range of healthcare services and rates that affect spending in this area. The National Pharmaceutical Council (NPC), a pharma-funded research organization, is partnering with the independent journal Health Affairs to examine the root causes of rising healthcare outlays in the United States. This two-year program will support academic and professional research projects and commentaries to be published and disseminated online by the journal.

  • 15 February 2018

    FDA Releases Guidance on Systemic Antibacterial Drugs

    FDA published guidance on the development, analysis, and presentation of microbiology data during the development of antibacterial drugs. The agency discusses the overall microbiology development program it says is needed to support clinical development and approval of antibacterial drugs administered systemically. The guidance also addresses microbiology data collected after drug approval.

Read more